Insider Ledger
RVMD insider buying and SEC filings, explained
Revolution Medicines, Inc. · CIK 1628171
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq, Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$720K
Planned sales (10b5-1)
$154.0M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 26, 2026 | Planned (10b5-1) | Anthony Mancini (Chief Global Commercialization Officer) sold 2,310 shares at $186.99 ($432K), marked as a 10b5-1 plan trade. Holdings down 5% to 39,765 shares. | SEC filing Filed Oct 28, 2026, 6:00 PM ET |
| Sep 29, 2026 | Planned (10b5-1) | Alan B. Sandler (Chief Development Officer) sold 6,309 shares at about $202.14 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 11% to 52,559 shares. | SEC filing Filed Oct 1, 2026, 6:00 PM ET |
| Sep 25, 2026 | Planned (10b5-1) | Jeff Cislini (SVP & General Counsel) sold 765 shares at $207.32 ($159K), marked as a 10b5-1 plan trade. Holdings down 1% to 51,776 shares. | SEC filing Filed Sep 29, 2026 |
| Sep 24–25, 2026 | Planned (10b5-1) | Anthony Mancini (Chief Global Commercialization Officer) sold 3,708 shares between Sep 24 and Sep 25 at about $200.45 ($743K), marked as a 10b5-1 plan trade. Holdings down 9% to 39,765 shares. | SEC filing Filed Sep 28, 2026 |
| Sep 22, 2026 | Planned (10b5-1) | Elizabeth M. Anderson (Director) sold 10,143 shares at about $193.04 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 70% to 4,333 shares. | SEC filing Filed Sep 24, 2026 |
| Sep 18, 2026 | Planned (10b5-1) | Anthony Mancini (Chief Global Commercialization Officer) sold 1,764 shares at $196.94 ($347K), marked as a 10b5-1 plan trade. Holdings down 4% to 40,352 shares. | SEC filing Filed Sep 22, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Anthony Mancini (Chief Global Commercialization Officer) sold 1,774 shares at about $199.24 ($353K), marked as a 10b5-1 plan trade. Holdings down 4% to 42,116 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Jeff Cislini (SVP & General Counsel) sold 3,366 shares at about $199.23 ($671K), marked as a 10b5-1 plan trade. Holdings down 6% to 52,541 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Alan B. Sandler (Chief Development Officer) sold 341 shares at about $199.24 ($68K), marked as a 10b5-1 plan trade. Holdings down 1% to 52,868 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Jack Anders (CFO) sold 4,053 shares at about $199.24 ($808K), marked as a 10b5-1 plan trade. Holdings down 3% to 119,216 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Stephen Michael Kelsey (CEO) sold 5,569 shares at about $199.23 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 2% to 286,307 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Margaret A Horn (President / COO) sold 4,967 shares at about $199.23 ($990K), marked as a 10b5-1 plan trade. Holdings down 3% to 149,680 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 13,988 shares at about $199.23 ($2.8M), marked as a 10b5-1 plan trade. Holdings down 5% to 253,342 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 11, 2026 | Planned (10b5-1) | Stephen Michael Kelsey (CEO) sold 92,531 shares at about $202.36 ($18.7M), marked as a 10b5-1 plan trade. Holdings down 24% to 291,876 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 10, 2026 | Planned (10b5-1) | Anthony Mancini (Chief Global Commercialization Officer) sold 15,448 shares at about $204.16 ($3.2M), marked as a 10b5-1 plan trade. Holdings down 26% to 43,890 shares. | SEC filing Filed Sep 14, 2026 |
| Sep 8, 2026 | Planned (10b5-1) | Lorence H. Kim (Director) sold 17,090 shares indirectly (by trust) at about $209.82 ($3.6M), marked as a 10b5-1 plan trade. Holdings by trust down 100% to 0 shares. | SEC filing Filed Sep 10, 2026 |
| Aug 31, 2026 | Planned (10b5-1) | Lorence H. Kim (Director) sold 56,000 shares indirectly (by trust) at about $203.24 ($11.4M), marked as a 10b5-1 plan trade. Holdings by trust down 77% to 17,090 shares. | SEC filing Filed Sep 2, 2026 |
| Aug 21, 2026 | Planned (10b5-1) | Jeff Cislini (General Counsel) sold 56,894 shares at about $209.24 ($11.9M), marked as a 10b5-1 plan trade. Holdings down 50% to 55,907 shares. | SEC filing Filed Aug 25, 2026 |
| Aug 21, 2026 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 86,000 shares directly and indirectly (by trust) at about $209.20 ($18.0M), marked as a 10b5-1 plan trade. Direct holdings down 23% to 267,330 shares. | SEC filing Filed Aug 25, 2026 |
| Jun 29, 2026 | Planned (10b5-1) | Sushil Patel (Director) sold 5,580 shares at about $187.99 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 20% to 21,656 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 24, 2026 | Planned (10b5-1) | Jack Anders (CFO) sold 20,000 shares at about $168.33 ($3.4M), marked as a 10b5-1 plan trade. Holdings down 14% to 123,269 shares. | SEC filing Filed Jun 26, 2026 |
| Jun 16, 2026 | Sale | Anthony Mancini (Chief Global Commercialization Officer) sold 4,615 shares at about $156.12 ($720K). Holdings down 8% to 49,975 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 18, 2026 |
| Jun 16, 2026 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 10,020 shares at about $156.12 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 4% to 267,330 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 16, 2026 | Planned (10b5-1) | Jeff Cislini (General Counsel) sold 2,157 shares at about $156.12 ($337K), marked as a 10b5-1 plan trade. Holdings down 4% to 56,521 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 16, 2026 | Planned (10b5-1) | Jack Anders (CFO) sold 2,722 shares at about $156.12 ($425K), marked as a 10b5-1 plan trade. Holdings down 2% to 123,269 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 16, 2026 | Planned (10b5-1) | Stephen Michael Kelsey (President / COO) sold 4,175 shares at about $156.12 ($652K), marked as a 10b5-1 plan trade. Holdings down 1% to 291,876 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 16, 2025–Jun 17, 2026 | Planned (10b5-1) | Margaret A Horn (President / COO) sold 93,575 shares between Jun 16, 2025 and Jun 17 at about $160.00 ($15.0M), marked as a 10b5-1 plan trade. Holdings down 38% to 154,647 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 11, 2026 | Planned (10b5-1) | Margaret A Horn (President / COO) sold 10,000 shares at about $148.01 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 6% to 158,222 shares. | SEC filing Filed Jun 15, 2026 |
| May 26, 2026 | Planned (10b5-1) | Anthony Mancini (Chief Global Commercialization Officer) sold 3,121 shares at about $153.99 ($481K), marked as a 10b5-1 plan trade. Holdings down 5% to 54,400 shares. | SEC filing Filed May 28, 2026 |
| Apr 27, 2026 | Planned (10b5-1) | Anthony Mancini (Chief Global Commercialization Officer) sold 3,120 shares at about $132.41 ($413K), marked as a 10b5-1 plan trade. Holdings down 5% to 54,400 shares. | SEC filing Filed Apr 29, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 120,000 shares at about $150.09 ($18.0M), marked as a 10b5-1 plan trade. Holdings down 30% to 276,698 shares. | SEC filing Filed Apr 17, 2026 |
| Mar 25, 2026 | Planned (10b5-1) | Anthony Mancini (Chief Global Commercialization Officer) sold 37,450 shares at about $95.57 ($3.6M), marked as a 10b5-1 plan trade. Holdings down 41% to 54,400 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | Lin Wei (Chief Medical Officer) sold 2,073 shares at $99.48 ($206K), marked as a 10b5-1 plan trade. Holdings down 2% to 101,366 shares. | SEC filing Filed Mar 19, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | Stephen Michael Kelsey (President / COO) sold 4,302 shares at $99.48 ($428K), marked as a 10b5-1 plan trade. Holdings down 1% to 295,398 shares. | SEC filing Filed Mar 19, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 12,871 shares at $99.48 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 4% to 276,698 shares. | SEC filing Filed Mar 19, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | Margaret A Horn (President / COO) sold 4,583 shares at $99.48 ($456K), marked as a 10b5-1 plan trade. Holdings down 3% to 157,570 shares. | SEC filing Filed Mar 19, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | Jack Anders (CFO) sold 2,753 shares at $99.48 ($274K), marked as a 10b5-1 plan trade. Holdings down 2% to 125,512 shares. | SEC filing Filed Mar 19, 2026 |
| Mar 17–19, 2026 | Planned (10b5-1) | Jeff Cislini (General Counsel) sold 2,958 shares between Mar 17 and Mar 19 at about $98.68 ($292K), marked as a 10b5-1 plan trade. Holdings down 5% to 58,518 shares. | SEC filing Filed Mar 19, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | Xiaolin Wang (Officer) sold 2,010 shares at $99.48 ($200K), marked as a 10b5-1 plan trade. Holdings down 2% to 116,063 shares. | SEC filing Filed Mar 19, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 36,000 shares directly and indirectly (by trust) at about $101.23 ($3.6M), marked as a 10b5-1 plan trade. Direct holdings down 9% to 289,569 shares. | SEC filing Filed Mar 3, 2026 |
| Jan 21, 2026 | Planned (10b5-1) | Jeff Cislini (General Counsel) sold 908 shares at $115.60 ($105K), marked as a 10b5-1 plan trade. Holdings down 2% to 46,976 shares. | SEC filing Filed Jan 23, 2026 |
| Jan 7, 2026 | Planned (10b5-1) | Margaret A Horn (President / COO) sold 75,000 shares at about $100.56 ($7.5M), marked as a 10b5-1 plan trade. Holdings down 35% to 141,053 shares. | SEC filing Filed Jan 9, 2026 |
| Jan 7, 2026 | Planned (10b5-1) | Jack Anders (CFO) sold 10,000 shares at $98.00 ($980K), marked as a 10b5-1 plan trade. Holdings down 8% to 108,065 shares. | SEC filing Filed Jan 9, 2026 |
| Dec 16, 2025 | Planned (10b5-1) | Jeff Cislini (General Counsel) sold 2,688 shares at $76.82 ($206K), marked as a 10b5-1 plan trade. Holdings down 5% to 47,884 shares. | SEC filing Filed Dec 18, 2025 |
| Dec 16, 2025 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 15,394 shares at $76.82 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 6% to 232,469 shares. | SEC filing Filed Dec 18, 2025 |
| Dec 16, 2025 | Planned (10b5-1) | Stephen Michael Kelsey (President / COO) sold 5,447 shares at $76.82 ($418K), marked as a 10b5-1 plan trade. Holdings down 2% to 278,600 shares. | SEC filing Filed Dec 18, 2025 |
| Dec 16, 2025 | Planned (10b5-1) | Margaret A Horn (President / COO) sold 4,847 shares at $76.82 ($372K), marked as a 10b5-1 plan trade. Holdings down 3% to 141,053 shares. | SEC filing Filed Dec 18, 2025 |
| Dec 16, 2025 | Planned (10b5-1) | Jack Anders (CFO) sold 3,104 shares at $77.09 ($239K), marked as a 10b5-1 plan trade. Holdings down 3% to 108,065 shares. | SEC filing Filed Dec 18, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Jack Anders (CFO) sold 5,418 shares at $74.00 ($401K), marked as a 10b5-1 plan trade. Holdings down 5% to 110,994 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 66,000 shares directly and indirectly (by trust) at about $75.07 ($5.0M), marked as a 10b5-1 plan trade. Direct holdings down 19% to 247,863 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 18, 2025 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 20,000 shares at about $70.38 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 7% to 247,863 shares. | SEC filing Filed Nov 20, 2025 |
| Nov 18, 2025 | Planned (10b5-1) | Jeff Cislini (General Counsel) sold 13,388 shares at about $70.14 ($939K), marked as a 10b5-1 plan trade. Holdings down 21% to 50,425 shares. | SEC filing Filed Nov 20, 2025 |
| Nov 12, 2025 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 20,000 shares at about $65.07 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 7% to 247,863 shares. | SEC filing Filed Nov 14, 2025 |
| Nov 11, 2025 | Planned (10b5-1) | Jack Anders (CFO) sold 10,000 shares at $64.00 ($640K), marked as a 10b5-1 plan trade. Holdings down 8% to 110,994 shares. | SEC filing Filed Nov 13, 2025 |
| Nov 7, 2025 | Planned (10b5-1) | Mark A. Goldsmith (CEO and Director) sold 30,000 shares at about $60.31 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 8% to 347,863 shares. | SEC filing Filed Nov 12, 2025 |
41 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow RVMD in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.